Dr. Zhengfu Fan 樊征夫
Chief Physician
Department of Bone and Soft Tissue Tumors, Peking University Cancer Hospital, Beijing
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Treatment of bone tumors, spinal tumors, soft tissue tumors, and bone metastases. Focuses on limb-sparing surgery, multidisciplinary care for sarcomas, and management of bone metastases.
Dr. Fan is Chief Physician and Director of the Bone and Soft Tissue Tumor Department at Peking University Cancer Hospital. Dr. Fan holds a PhD from West China Medical Center. Dr. Fan completed visiting scholar positions at Cleveland Clinic and MD Anderson Cancer Center. Dr. Fan's research includes tissue-engineered bone vascularization and sarcoma genetics.
Professional roles
- Member, Chinese Medical Association
- Vice Chair, Bone and Soft Tissue Tumor Committee, Beijing Anti-Cancer Association
- Committee Member, Bone and Soft Tissue Sarcoma Expert Committee, Chinese Society of Clinical Oncology (CSCO)
- Standing Committee Member, Sarcoma Committee, China Anti-Cancer Association
Name order: in Chinese the family name comes first (Fan Zhengfu). Papers usually list the name as Zhengfu Fan or Fan Z.
Selected publications
38 papers on PubMed matched by name and affiliation; 7 as first or senior author since 2016. Most recent first- or senior-author papers:
- Genes Chromosomes Cancer, 2026 (senior author): Synovial Sarcoma With BRAF V600E Mutation: A Case Report and Literature Review. PubMed 42084470
- EClinicalMedicine, 2025 (first author): Safety and efficacy of HH2853, a novel EZH1/2 dual inhibitor, in patients with refractory solid tumours or non-Hodgkin lymphomas: a phase I study. PubMed 40821900
- Anticancer Drugs, 2024 (senior author): Targeting MCM2 activates cancer-associated fibroblasts-like phenotype and affects chemo-resistance of liposarcoma cells against doxorubicin. PubMed 39109389
- J Cancer Res Clin Oncol, 2022 (senior author): A novel TMTC2-NTRK3 fusion in undifferentiated high-grade pleomorphic sarcoma. PubMed 35933643
- Neoplasma, 2022 (senior author): SNHG9/miR-214-5p/SOX4 feedback loop regulates osteosarcoma progression. PubMed 36004648
- Cancer Biol Med, 2020 (senior author): KIF18B promotes tumor progression in osteosarcoma by activating β-catenin. PubMed 32587775
- Nan Fang Yi Ke Da Xue Xue Bao, 2016 (first author): [Low-dose methotrexate combined with vinorelbine for inoperable desmoid tumor: efficacy and the prognostic factors]. PubMed 26806736
- Clin Orthop Relat Res, 2015 (first author): Should High-grade Extraosseous Osteosarcoma Be Treated With Multimodality Therapy Like Other Soft Tissue Sarcomas?. PubMed 26197952
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion